HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
2- (4- isothiocyanatobenzyl)- 6- methyldiethylenetriaminepentaacetic acid
a bifunctional chelating agent
Also Known As:
1B4M-DTPA; 2-(p-SCN-Bz)-6-methyl-DTPA; Mx-DTPA
Networked:
5
relevant articles (
0
outcomes,
0
trials/studies)
Bio-Agent Context: Research Results
Organic Chemicals: 133
Amines: 4871
Polyamines: 3918
Pentetic Acid: 1751
2-(4-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid: 5
Carboxylic Acids: 973
Acyclic Acids
Acetates: 4994
Pentetic Acid: 1751
2-(4-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid: 5
Related Diseases
1.
Neoplasms (Cancer)
01/01/1991 - "
Tumor-to-liver ratios rose as a function of time for 1B4M-DTPA, 1M3B-DTPA and 1B3M-DTPA MAb chelate conjugates with virtually no accumulation of the radiometal into this organ, as revealed by no increase in the liver-to-blood values.
"
07/01/1994 - "
B3 was conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M) or 2-(p-SCN-Bz)-1,4,7,10 tetraazacyclododecane tetra-acetic acid (2B-DOTA) and labeled with 111In at 1.4-2.4 mCi/mg and 88Y at 0.1-0.3 mCi/mg. Non-tumor-bearing nude mice were co-injected i.v. with 5-10 microCi/4-10 micrograms of 111In/88Y-labeled B3 conjugates and sacrificed at 6 h and daily up to 168 h post-injection.
"
07/01/1993 - "
Patients received 5 mCi (185 MBq) of 111In-methyl benzyl isothiocyanate DTPA (MX-DTPA) conjugated BrE-3 Mab intravenously with total antibody doses of 10, 50 or 100 mg. Serial quantitative imaging, blood and urine clearance were obtained to measure pharmacokinetics, assess tumor localization and estimate radiation dose.
"
01/01/1991 - "
The results reviewed here, and described previously (Roselli et al., 1991) demonstrate that the use in vivo of backbone-substituted forms of the SCN-Bz-DTPA, such as 1B4M-DTPA, 1M3B-DTPA, and 1B3M-DTPA bound to MAbs, can reduce uptake of indium to normal organs while maximizing the dose to tumor.
"
07/01/1998 - "
To evaluate radiometal-labeled humanized BrE-3 (huBrE-3) monoclonal antibody as a radioimmunolocalization and therapeutic agent in breast cancer patients, tumor localization, pharmacokinetics, radiation dosimetry, and immunogenicity of (111)In-labeled combined 1-p-isothiocyanatobenzyl 3-methyl- and 1-p-isothiocyanatobenzyl 4-methyldiethylenetriamine pentaacetic acid (MX-DTPA) huBrE-3 were studied.
"
2.
Breast Neoplasms (Breast Cancer)
07/01/1998 - "
Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer.
"
08/01/1997 - "
Indium-111/yttrium-90-MX-DTPA BrE-3 can be safely administered to patients with metastatic breast cancer, and therapy doses yielded pharmacokinetics similar to those of tracer doses.
"
07/01/1998 - "
To evaluate radiometal-labeled humanized BrE-3 (huBrE-3) monoclonal antibody as a radioimmunolocalization and therapeutic agent in breast cancer patients, tumor localization, pharmacokinetics, radiation dosimetry, and immunogenicity of (111)In-labeled combined 1-p-isothiocyanatobenzyl 3-methyl- and 1-p-isothiocyanatobenzyl 4-methyldiethylenetriamine pentaacetic acid (MX-DTPA) huBrE-3 were studied.
"
Related Drugs and Biologics
1.
Indium
2.
Acetic Acid (Vinegar)
3.
Yttrium
4.
Pentetic Acid (DTPA)
5.
Monoclonal Antibodies
6.
Acids
7.
1- (4- isothiocyanatobenzyl)diethylenetriaminepentaacetic acid
8.
benzyl isothiocyanate
Related Therapies and Procedures
1.
Therapeutics